{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT02456480",
      "orgStudyIdInfo": {
        "id": "CLS001-CO-PR-008"
      },
      "secondaryIdInfos": [
        {
          "id": "2014-003689-26",
          "type": "EUDRACT_NUMBER"
        }
      ],
      "organization": {
        "fullName": "Maruho Co., Ltd.",
        "class": "INDUSTRY"
      },
      "briefTitle": "Pharmacodynamics of Omiganan (CLS001) in Patients With Atopic Dermatitis",
      "officialTitle": "A Randomized, Double-blind, Placebo Controlled Study to Assess the Pharmacodynamics, Safety/Tolerability and Efficacy of Omiganan in Patients With Mild to Moderate Atopic Dermatitis"
    },
    "statusModule": {
      "statusVerifiedDate": "2016-07",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2015-05"
      },
      "primaryCompletionDateStruct": {
        "date": "2015-11",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2015-11",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2015-05-01",
      "studyFirstSubmitQcDate": "2015-05-26",
      "studyFirstPostDateStruct": {
        "date": "2015-05-28",
        "type": "ESTIMATED"
      },
      "dispFirstSubmitDate": "2016-07-25",
      "dispFirstSubmitQcDate": "2016-07-25",
      "dispFirstPostDateStruct": {
        "date": "2016-07-28",
        "type": "ESTIMATED"
      },
      "lastUpdateSubmitDate": "2016-07-25",
      "lastUpdatePostDateStruct": {
        "date": "2016-07-28",
        "type": "ESTIMATED"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "Maruho Co., Ltd.",
        "class": "INDUSTRY"
      }
    },
    "oversightModule": {
      "oversightHasDmc": false
    },
    "descriptionModule": {
      "briefSummary": "To assess the pharmacodynamics, safety/tolerability, and efficacy of omiganan in patients with mild to moderate atopic dermatitis (AD)."
    },
    "conditionsModule": {
      "conditions": [
        "Atopic Dermatitis"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "QUADRUPLE",
          "whoMasked": [
            "PARTICIPANT",
            "CARE_PROVIDER",
            "INVESTIGATOR",
            "OUTCOMES_ASSESSOR"
          ]
        }
      },
      "enrollmentInfo": {
        "count": 37,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "CLS001 topical gel, 2.5%",
          "type": "EXPERIMENTAL",
          "interventionNames": [
            "Drug: CLS001"
          ]
        },
        {
          "label": "CLS001 topical gel 1%",
          "type": "EXPERIMENTAL",
          "interventionNames": [
            "Drug: CLS001"
          ]
        },
        {
          "label": "Vehicle gel",
          "type": "PLACEBO_COMPARATOR",
          "interventionNames": [
            "Drug: Vehicle"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "CLS001",
          "description": "topical gel",
          "armGroupLabels": [
            "CLS001 topical gel 1%",
            "CLS001 topical gel, 2.5%"
          ]
        },
        {
          "type": "DRUG",
          "name": "Vehicle",
          "description": "topical gel",
          "armGroupLabels": [
            "Vehicle gel"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Pharmacodynamic (Local punch biopsy of a target lesion pre-dose and post treatment for the change in biomarkers including IL, filaggrin, TLR, IgE, IFN, and microbiome of the skin lesion)",
          "description": "Local punch biopsy of a target lesion pre-dose and post treatment for the change in biomarkers including IL, filaggrin, TLR, IgE, IFN, and microbiome of the skin lesion",
          "timeFrame": "42 Days"
        },
        {
          "measure": "Clinical assessment (Change in patient symptoms over time using pruritis VAS)",
          "description": "Change in patient symptoms over time using pruritis VAS",
          "timeFrame": "42 Days"
        },
        {
          "measure": "Clinical Assessment (Change in lesion size over time)",
          "description": "Change in lesion size over time",
          "timeFrame": "42 Days"
        },
        {
          "measure": "Clinical assessment (Change in patient SCORAD scale score over time)",
          "description": "Change in patient SCORAD scale score over time",
          "timeFrame": "42 Days"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Safety Assessment (Adverse events)",
          "description": "Adverse events will be collected throughout the study",
          "timeFrame": "42 days"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n1. Male and female subjects with mild to moderate AD 18 to 65 years of age, inclusive.\n2. AD diagnosed by physician / medical specialist and that has been (intermittently) present for at least 1 year\n3. Able to participate and willing to give written informed consent and to comply with the study restrictions.\n\nExclusion Criteria:\n\n1. Have any current and / or recurrent clinically significant skin condition in the treatment area other than AD.\n2. Any confirmed, active significant allergic reactions (urticaria or anaphylaxis) including allergic reactions against any drug, multiple drug allergies or (ingredients of) emollients.\n3. Participation in an investigational drug or device study within 3 months prior to screening or more than 4 times a year.",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "maximumAge": "65 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "J. (Koos) Burggraaf, MD, PhD",
          "affiliation": "Centre for Human Drug Research",
          "role": "PRINCIPAL_INVESTIGATOR"
        }
      ],
      "locations": [
        {
          "facility": "Centre for Human Drug Research",
          "city": "Zernikedreef 8",
          "country": "Netherlands"
        }
      ]
    },
    "referencesModule": {
      "references": [
        {
          "pmid": "32315497",
          "type": "DERIVED",
          "citation": "Niemeyer-van der Kolk T, van der Wall H, Hogendoorn GK, Rijneveld R, Luijten S, van Alewijk DCJG, van den Munckhof EHA, de Kam ML, Feiss GL, Prens EP, Burggraaf J, Rissmann R, van Doorn MBA. Pharmacodynamic Effects of Topical Omiganan in Patients With Mild to Moderate Atopic Dermatitis in a Randomized, Placebo-Controlled, Phase II Trial. Clin Transl Sci. 2020 Sep;13(5):994-1003. doi: 10.1111/cts.12792. Epub 2020 May 1."
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D003876",
          "term": "Dermatitis, Atopic"
        }
      ],
      "ancestors": [
        {
          "id": "D012873",
          "term": "Skin Diseases, Genetic"
        },
        {
          "id": "D030342",
          "term": "Genetic Diseases, Inborn"
        },
        {
          "id": "D009358",
          "term": "Congenital, Hereditary, and Neonatal Diseases and Abnormalities"
        },
        {
          "id": "D003872",
          "term": "Dermatitis"
        },
        {
          "id": "D012871",
          "term": "Skin Diseases"
        },
        {
          "id": "D017437",
          "term": "Skin and Connective Tissue Diseases"
        },
        {
          "id": "D017443",
          "term": "Skin Diseases, Eczematous"
        },
        {
          "id": "D006969",
          "term": "Hypersensitivity, Immediate"
        },
        {
          "id": "D006967",
          "term": "Hypersensitivity"
        },
        {
          "id": "D007154",
          "term": "Immune System Diseases"
        }
      ]
    }
  },
  "hasResults": false
}